Hepatopulmonary syndrome (HPS) in stable patients with cirrhosis can easily be overlooked. We report on the presenting symptoms, disease progression, and outcomes after liver transplantation (lt) in children with HPS. twenty patients were diagnosed with HPS between 1996 and 2016. the etiologies were as follows: biliary atresia (n = 9); alpha-1-antitrypsin deficiency (n = 2); cryptogenic liver disease (n = 3); and others (n = 6). HPS presentations were as follows: dyspnea (n = 17) and pneumonia (n = 3). For diagnostic confirmation, the following techniques were used: technetium-99m-labeled macroaggregated albumin lung perfusion scan (n = 13) or contrast echocardiogram (n = 7). there were 16 patients listed for lt, with a median age at HPS diagnosis of 10 years and an average wait from listing to lt of 9 weeks. a marked rise in hemoglobin (Hb; median, 125-143.5 g/l) and modest decrease in oxygen saturation (SpO 2 ; median 91% to 88% room air) were evident over this time. Patients' need for assisted ventilation (1 day), pediatric intensive care unit (PicU) stay (3 days), and total hospital stay (20 days) were similar to our general lt recipients-the key difference in the postoperative period was the duration of supplementary O 2 requirement. Hb of ≥130 g/l on the day of lt correlated with a longer PicU stay (P value = 0.02), duration of supplementary O 2 (P value = 0.005), and the need for the latter beyond 7 days after lt (P value = 0.01). Fifteen patients had resolution of their HPS after lt. the 5-, 10-, and 20-year survival rates were unchanged at 87.5%. none had a recurrence of HPS. in conclusion, HPS is a life-threatening complication of cirrhosis which usually develops insidiously. this combined with the often-stable nature of the liver disease leads to delays in diagnosis and listing for lt. Progressive polycythemia extends the need for supplementary O 2 and PicU stay. We advocate screening for HPS with a combination of SpO 2 and Hb monitoring to facilitate earlier recognition, timely lt, and shortened recovery periods. Hepatopulmonary syndrome (HPS) occurs in the setting of chronic liver disease regardless of the etiology.
Hepatopulmonary syndrome (HPS) occurs in the setting of chronic liver disease regardless of the etiology.
Although portal hypertension is commonly present, (1) (2) (3) patients with HPS often have stable liver disease with normal liver function biochemically and no evidence of decompensation such as jaundice, ascites, coagulopathy, or hepatic encephalopathy. (2) (3) (4) Prevalence in adults with HPS is quoted at between 4% and 32%, and 10%-20% of children with chronic liver disease may be affected. (4, 5) The diagnosis of HPS consists of the finding of intrapulmonary vascular dilatation (IPVD) and impaired oxygenation in the setting of chronic liver disease and/ or portal hypertension. (3, 4, 6) The recommended cutoff values for HPS diagnosis are partial pressure of arterial oxygen (PaO 2 ) < 80 mm Hg or PAaO 2 >15 mm Hg, whereby PaO 2 is the arterial partial pressure of oxygen and PAaO 2 is the alveolar-arterial oxygen gradient. (6) The European Respiratory Society Task Force has classified HPS severity into the following stages (6) : mild, PaO 2 ≥80 mm Hg; moderate, ≥60 to <80 mm Hg; severe, ≥50 to <60 mm Hg; and very severe, <50 mm Hg.
Pulse oximetry has been validated as a screening tool in HPS patients with cirrhosis; a threshold of ≤97% has been shown to detect a PaO 2 level of <70 mm Hg with a sensitivity of 100% and a specificity of 65%. (6, 7) However, patients with subclinical HPS, ie, IPVD without hypoxemia or those with mild HPS, may have normal oxygen saturations (SpO 2 >98%). (6, 7) Measuring the PaO 2 and PAaO 2 are more accurate measures of hypoxemia. However, arterial blood gas (ABG) sampling is impractical in children and entails significant complications such as hematoma formation and arteriospasm. Hyperemic capillary blood gas (CBG) analysis is shown to correlate well with arterial partial pressure of oxygen. (8) This is performed in children by sampling from the ear lobe after application of local anesthetic. Although the overall sensitivity for CBG is acceptable at 94%, the specificity is only 53%; this results in a falsely elevated PAaO 2 . Specificity drops to 25% in children <2 years of age. (8) The underlying pathophysiology of HPS is not well understood but is postulated to be driven by an excess of endogenous vasodilators such as nitric oxide (NO). Cholangiocytes have been demonstrated to increase production of endothelin 1 (ET-1) in animal experimental models of common bile duct ligation. This in turn is mirrored by up-regulation of endothelin B receptors (ET B Rs) in the pulmonary vasculature, which binds to this ET-1 in the circulation. (3) (4) (5) (6) The ET B R/ET-1 complex induces NO production via endothelial NO synthase. (3) (4) (5) (6) (7) Supportive evidence of this occurring in humans is the higher concentration of exhaled NO levels recorded in patients with HPS, with levels returning to normal after liver transplantation (LT). (4) (5) (6) These vasoactive substances cause abnormal vascular dilatation at the level of the pulmonary capillary beds, most prominently at the base of the lungs, which results in ventilation-perfusion mismatch and hypoxemia. (2) (3) (4) (5) There is also mounting evidence that angiogenesis has an important role to play in HPS pathogenesis. (6, 7) The key diagnostic tests for HPS in children are technetium-99m-labeled macroaggregated albumin lung perfusion scan ( 99m Tc-MAA) and contrast echocardiogram, with the latter considered the gold standard. Both investigations are routinely performed when HPS is suspected; contrast echocardiography enables 4-dimensional real-time diagnosis and the shunt index derived from the 99m Tc-MAA lung scan provides a quantitative measure of the severity. (3) (4) (5) (6) (7) Pulmonary arteriography is not routinely performed in children because it is an invasive procedure with inherent risks of cardiac catheterization in addition to general anesthesia in patients who already have respiratory compromise and impaired oxygenation.
Progressive symptoms and the need for home domiciliary oxygen can have a tremendous negative impact on the patient's quality of life and if left untreated, the condition becomes life-threatening. LT is curative and is the only viable treatment option for HPS.
The aim of this study is to report on the presenting symptoms of children with HPS, disease progression while on the waiting list for LT, and the outcomes of LT, including an evaluation of clinical factors which predict duration of oxygen dependency after LT.
Patients and Methods
Twenty patients were identified between 1996 to 2016 in which the indication for LT was HPS. A retrospective study of the clinical records was performed by review of the electronic patient database including nuclear medicine and echocardiogram reports, laboratory results, and patient charts and clinical notes from archives. The project was registered as a retrospective audit study with the local institutional review committee.
The underlying liver condition, age at HPS diagnosis, sex, presenting symptoms of HPS, SpO 2 , hemoglobin (Hb), and mode of diagnosis are shown in Table 1 Table 2 . PELD and MELD scores are medical scoring systems of disease severity which provide a risk of mortality and help prioritize patients on the transplant waiting list. (9) Information was collected on the following:
1. Disease progression, ie, SpO 2 in room air (RA) and Hb level (g/L) from HPS diagnosis through to LT. 2. Post-LT outcome with respect to number of days on the ventilator, length of pediatric intensive care unit (PICU) stay, total hospital stay, duration of oxygen supplementation, complications after LT, and survival (Table 3) .
DIAGnOSTIC CrITErIA FOr HPS
For chronic liver disease patients to be included in the study, 1 of the following criteria was present:
1. Contrast echocardiogram in which agitated saline injected into a proximal peripheral vein appears as the presence of microbubbles seen in the left atrium within 3-6 cardiac cycles (n = 7). (3,4) 2. 99m Tc-MAA (n = 13).
In the 99m Tc-MAA lung scan, Tc-99 is normally absorbed in the lungs, with uptake elsewhere in the body such as the brain signifying intrapulmonary shunting. Brain uptake of >2% is abnormal and taken to be diagnostic of HPS in children. (3, 4) SpO 2 is not included in the diagnosis because of the following:
1. Patients may have subclinical/mild HPS despite normoxia. 2. Hypoxia may be secondary to ascites or restrictive lung disease, eg, pleural effusions.
All patients were screened for cardiac and respiratory structural abnormalities as part of their investigative workup, including a chest radiograph and 2-dimensional transthoracic echocardiogram.
AnAlYSIS AnD STATISTICS
Descriptive statistics convey the demographic data for all 20 patients: median (range) and interquartile range (25th to 75th percentiles). Correlation analysis was performed using Graphpad Prism version 6 (GraphPad Software, La Jolla, CA) on the 16 patients who underwent LT with results of the Spearman's coefficient regression analysis on the shunt index at diagnosis; length of wait from HPS diagnosis to LT; degree of hypoxia and polycythemia on the day of transplantation against post-LT outcomes (duration of ventilator dependency, length of PICU stay, length of hospitalization, and length of oxygen supplementation); and Fisher's exact test on the variables in the 2 by 2 contingency tables (Supporting Table) .
results

PrESEnTInG SYMPTOMS OF CHIlDrEn WITH HPS (n = 20)
The presenting symptoms were breathlessness with daily activities such as walking to school (n = 17) and pneumonia (n = 3; Table 1 ). Central cyanosis was found in 8 patients. Diagnosis was confirmed by 99m Tc-MAA lung scan (n = 13) or contrast echocardiogram (n = 7). The majority of children were female (65%, n = 13) and older than 5 years of age (70%, n = 14). Half the patients with biliary atresia (BA) had biliary atresia with a splenic malformation (BASM; 56%, 5 out of 9 patients).
A total of 15 patients had stable liver disease; 5 had overt signs of decompensated liver disease with ascites, worsening jaundice, growth failure, and an albumin level of 32 g/L ( Table 2) . None of the patients had PELD or MELD scores exceeding 25; PELD score range was -10 to 10 and the MELD score range was 6-15 ( Table 2) . *Immune dysregulation (n = 2); autoimmune hepatitis (n = 1); PFIC type 3 (n = 1); Budd-Chiari (n = 1); and Abernethy malformation (n = 1).
The low scores reflect the clinical status of these patients, the majority of whom were well from the perspective of their liver disease. HPS is, however, a PELD and MELD exception as their liver disease status may not reflect the true morbidity and risk of mortality of these patients due to this disease complication.
Sixteen patients were placed on the LT waiting list. A total of 4 patients were excluded from transplantation because of life-limiting comorbidities in 3 (factor 12 deficiency with catastrophic intracranial hemorrhage following a head injury, Abernathy malformation associated with cerebral abscess, and complex immune dysregulation), and resolution of Budd-Chiari syndrome by hepatic vein balloon dilatation in 1. A total of 11 patients had established cirrhosis in their explant histology; 3 had moderate fibrosis. We were unable to retrieve the histology reports of 2 patients transplanted for HPS in the 1990s.
ClInICAl PrOGrESSIOn DUrInG THE WAIT FOr lT (n = 16)
Patients waited an average of 6 weeks (range, 1-19 weeks) from HPS diagnosis to listing and 17 weeks (range, 6-77 weeks) from diagnosis to LT.
During the wait for LT, 13/16 (81%) patients became more dyspneic of whom 9 of the 13 (69%) required home oxygen and 2 experienced recurrent lower respiratory tract infections. A general trend toward a drop in median SpO 2 from 91% to 88% in RA and a rise in median Hb from 125 to 143.5 g/L was observed (Fig. 1) . A total of 15 patients made a full recovery and were discharged home from the hospital; 1 patient died at day 10 after LT from multiorgan failure secondary to presumed sepsis. All 15 patients needed supplementary oxygen after LT for a median of 12 days. This differs from our general transplant cohort for which supplementary oxygen requirement is for no more than 48 hours. Seven patients needed supplementary oxygen for ≥14 days, of whom 4 went on to need home domiciliary oxygen after LT.
There was a statistically significant association between a Hb of >130 g/L on the day of LT with a longer length of supplementary oxygen requirement (P = 0.005) and PICU stay (P = 0.02).
The need for assisted ventilation and total hospital stay in the 15 survivors were similar to our general transplant cohort (Table 3) .
As a preventative measure against thrombosis of graft vessels, all patients received aspirin and dipyridamole after LT. Venesection was carried out if the Hb rose above 100 g/L (as per standard protocol). Eight patients required venesection after transplant and in addition, 12 patients were placed on a heparin infusion.
Two patients required surgical re-exploration during the transplant admission because of adverse Doppler flow measurements: 1 patient was found to have hepatic artery (HA) stenosis at day 3 after LT and the other had portal vein (PV) stenosis at day 10 after LT.
The patient with HA stenosis was a 14-year-old female who received a whole DCD liver graft for HPS in 1997. Her background was alpha-1-antitrypsin deficiency. A high baseline polycythemia of 154 g/L with a SpO 2 of 89% in RA was recorded prior to LT. No surgical intervention was required during the explorative laparotomy. Proactive measures to prevent hepatic artery thrombosis (HAT) were instituted including repeated prophylactic venesection, robust fluid management, heparin infusion, and transitioning onto warfarin treatment before discharge. Good Doppler HA flow was subsequently detected throughout the transplant admission.
At day 27, this patient presented with abdominal pain and low-grade fever. No HA signal was seen on ultrasound or computed tomography (CT) angiogram. The patient progressed onto a second LT for HAT; recovery was uneventful, and she has done extremely well since with no graft-related sequelae.
The patient with PV stenosis had successful revascularization of her PV at the explorative laparotomy. This patient was also commenced on warfarin treatment as were 3 others who had dampened hepatic vascular flows on Doppler ultrasound (HA, n = 1; hepatic vein, n = 2). Warfarin treatment is commenced on a case-by-case basis.
Late HAT developed in the other patient with dampened HA flow despite employing proactive HAT preventative measures and warfarin treatment. This patient was a 10-year-old male with BASM who had a whole DCD LT for HPS in 1999; the donor HA was noted to be small at 3-mm diameter, and an arterial graft from an iliac artery was used. He had significant baseline polycythemia with an Hb of 162 g/L (SpO 2 of 90% RA) before the LT. Doppler HA flow was satisfactory throughout, but he had increasing cholestasis and a transaminitis at 2.5 months after LT. His allograft biopsy was suggestive of ischemic cholangiopathy, and as his graft function worsened, he was regrafted at day 72 after his first LT.
Regarding other complications, one-third of patients had suspected sepsis after LT (5 of 16), which is similar to our general LT cohort. However, one-third of patients also had respiratory complications (pneumonia, n = 3; pulmonary edema, n = 2). This is more common than usually observed in our general LT patients. Other post-LT complications are shown in Fig. 2 .
Patients stayed in the hospital for an average of 20 days, which is comparable to the general transplant cohort (Table 3) . One outlier required hospitalization for 168 days because of chylous ascites, cytomegalovirus (CMV) hepatitis, and septic episodes; oxygen therapy was no longer needed at day 12 after LT.
An association between a raised Hb (Hb >130 g/L on the day of LT) and the need for supplemental oxygen beyond 7 days after LT was observed (P = 0.01; Table 4) . A relationship between severity of intrapulmonary shunting and duration of supplementary oxygen was not demonstrated in our HPS patients.
All patients were cured of their HPS; there has not been a recurrence of HPS. The 5-, 10-, and 20-year survival rates were unchanged at 87.5% (Fig. 3) . One patient died 2 weeks after LT from suspected sepsis, and a second patient with BASM died 1 year after LT from pneumococcal sepsis. Nine patients have been transitioned to adult hepatology. Five patients remain under pediatric care at our Liver Unit; 4 are clinically well; and 1 patient developed pulmonary hypertension 4 years after successful LT and resolution of HPS. Her liver allograft is entirely normal histologically and biochemically.
Discussion
The natural history of HPS is one of progressive decline; the 5-year survival in 1 adult study was only 23% without transplantation. (1, 3) Patients with HPS have a higher mortality and lower quality of life compared with chronic liver disease patients without HPS. (10) For these reasons, HPS is listed as a MELD exception. (9) HPS occurs in 10%-20% of children with chronic liver disease but is often overlooked until the late stages, as symptoms are subtle. (4, 5) This coupled with the frequent finding of well-compensated liver disease can be falsely reassuring. Delays in HPS diagnosis will place the child at greater risk of pretransplant morbidity Original article | 1277 from progressive polycythemia and eventual domiciliary home oxygen requirement. Our report has shown a statistically significant correlation between progressive pretransplant polycythemia and a longer dependency on supplementary oxygen and PICU stay after LT. Polycythemia is a strong risk factor for HAT, (11) which is a serious complication that often leads to graft loss. Two of our patients in this series had HAT, placing the incidence at 12.5%, which is higher than the expected incidence of HAT in the general transplant cohort of 9%. (12) Both had significant pretransplant polycythemia. This observation emphasizes the importance of early recognition and diagnosis of HPS before severe polycythemia develops, particularly in children with subclinical HPS who may have normal SpO 2 readings.
The key new finding this study adds to the knowledge, and thus, to the management of HPS in children, is the importance of pretransplant polycythemia as an indicator of longer PICU stay (P = 0.02) and supplemental oxygen requirement (P = 0.005) post-LT. The physiological response to chronic hypoxia may take many months to resolve. This should be taken into account in PICU algorithms for weaning patients from the ventilator; importantly extubation may be feasible in these patients even if they still have a high oxygen requirement.
The duration of post-LT supplementary O 2 requirement was on average 12 days, which greatly exceeds that of our general transplant cohort. Pretransplant counseling at our Liver Unit now includes this observation, which provides HPS patients and their families with a realistic timeframe for the duration of oxygen therapy after LT. Despite the apparent lengthy duration compared with our general LT patients, the need for supplementary O 2 in our HPS cohort is much less than that quoted in the literature for HPS patients, which is on average 3 months; supplementary O 2 requirement of >12 months has been reported. (6) The degree of hypoxia and shunt index did not reach statistical significance in our cohort. This may be due to the small sample size, which is a limitation of the study. It is important to highlight that the patient in our cohort with the longest supplementary oxygen requirement after LT of 139 days was a 9-year-old girl with BASM who had the highest shunt index recorded (46.4%) and an SpO 2 of 78% in RA on the day of LT.
Respiratory complications appeared more commonly observed compared with our general LT patients and may be a result of abnormal blood flow across the pulmonary capillary bed in the early post-LT period. (13, 14) Even with regrafting of 2 patients with HAT, the longterm outcome of our post-LT cohort for HPS is excellent. The 5-, 10-, and 20-year survival is unchanged at 87.5%. All patients were cured of their HPS, and there has not been a recurrence of HPS. Similar survival rates are reported by others. (15) None of our patients developed portopulmonary syndrome. In contrast to HPS, portopulmonary syndrome results in chronically raised pulmonary artery pressures (PAPs) from increased pulmonary vascular resistance. Although both disorders may improve after LT, advanced portopulmonary syndrome is a contraindication to LT. (15, 16) Only 25% (5 of the 20 patients) of our cohort had overt liver disease with jaundice, ascites, and growth failure at HPS diagnosis, which is consistent with other clinical reports. (3) (4) (5) This observation correlated with the low PELD and MELD scores found, which indicates a higher 12-month survival and lower 90-day mortality on the waiting list, respectively. (9) Notably, only 1 patient had a prothrombin time (PT) of >15 seconds, and 5 had an albumin level of <32 g/L. This is consistent with the finding that HPS commonly develops in the setting of well-compensated liver disease and highlights the importance of having a high index of suspicion for HPS.
Although platypnea is the classic symptom described in HPS (breathlessness that is improved/aborted when the patient lies flat (2) (3) (4) ), the primary symptom reported by our cohort was breathlessness experienced with daily activities, eg, mobilizing around the house and walking to school (85%, 17 out of 20). Five of these children had saturations in RA of <92%, necessitating domiciliary home oxygen at the time of diagnosis. Only 3 of the children were diagnosed with HPS following presentation with a chest infection.
Pediatric patients with subclinical HPS, ie, IPVD without hypoxemia or those with mild HPS, may have normoxia (SpO 2 >98%). (17) However, pulse oximetry remains important and should be monitored as emphasized by Kochar et al. who reported on serial SpO 2 readings from separate clinic visits of 22 HPS and 32 non-HPS adult patients with cirrhosis over a mean duration of 20 months. Their findings on HPS patients included the following:
1. Had lower SpO 2 at baseline and follow-up. 2. Were more likely to have ≥2% reduction in their SpO 2 readings at subsequent clinic visits. 3. Had a faster decline in SpO 2 over time. (10) The authors concluded that SpO 2 readings are useful for detecting and monitoring HPS progression. Pulse oximetry may not be as accurate as the PaO 2 or the calculated PAaO 2 from an ABG, but there are many advantages in using this modality in pediatric patients. It is an easily obtained, quick and painless noninvasive procedure that is reproducible and cost-/effective. (7) Serial Hb levels to screen for a rising trend, recorded along with SpO 2 readings at clinic visits, will be invaluable in raising the suspicion of HPS in patients with subtle symptoms. (13, 15) The majority of our cohort had liver disease from infancy and a median age of HPS diagnosis of 10 years, with only 6 patients <5 years of age. This observation contrasts with other authors who report HPS presentation at an earlier time point from the onset of their original disease. (3, 4) In conclusion, our study of HPS patients over a 20-year period shows the following:
1. The longer the child with HPS has to wait for a LT, the more polycythemic they will become and the longer they will need supplementary O 2 and PICU stay after LT. 2. There appears to be a higher risk of respiratory complications post-LT for HPS.
Pretransplant counseling of children with HPS
and their families should encompass these findings and possibly the need for posttransplant venesection, anticoagulation with warfarin, discharge home on supplemental oxygen, and even regrafting in some cases. 4. Proactive monitoring with serial pulse oximetry and Hb levels should be incorporated into protocols to encourage screening for HPS.
Early recognition will prevent delays in HPS diagnosis, facilitate timely workup for LT, and ensure a shorter recovery period after LT.
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